Advancing Value Assessment in the United States: A Multistakeholder Perspective

Value in Health

Volumn 20, Issue 2, 2017, Pages 299-307

  Sorenson, Corinna ^a   Lavezzari, Gabriela ^b   Daniel, Gregory ^b   Burkholder, Randy ^c   Boutin, Marc ^d   Pezalla, Edmund ^e   Sanders, Gillian ^a   McClellan, Mark ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY   (United States)

^c Pharmaceutical Research and Manufacturers of America   (United States)

^d National Health Council   (United States)

^e Enlightenment Bioconsult LLC   (United States)

Author keywords

health care decision makers; standards; value assessment; value for money

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; ECONOMIC MODEL; FUNCTIONAL STATUS; GENETIC VARIATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SHARED DECISION MAKING; UNITED STATES; BIOMEDICAL TECHNOLOGY ASSESSMENT; PRACTICE GUIDELINE; PURCHASING; STANDARDS; TOTAL QUALITY MANAGEMENT;

GUIDELINES AS TOPIC; HEALTH EXPENDITURES; QUALITY IMPROVEMENT; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES; VALUE-BASED PURCHASING;

EID: 85013638998     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.11.030     Document Type: Article

References (23)

1. [1] Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures. J Am Coll Cardiol 63 (2014), 2304–2322.
2. [2] Schnipper, L.E., Davidson, N.E., Wollins, D.S., et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33 (2015), 2563–2577.
3. [3] Institute for Clinical and Economic Review. ICER value assessment framework. Available from: https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/. [Accessed July 29, 2016].
4. [4] Memorial Sloan Kettering Cancer Center. DrugAbacus methods. Available from: http://www.drugabacus.org/drug-abacus/methods/. [Accessed August 3, 2016].
5. [5] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) with NCCN Evidence Blocks™. Available from: https://www.nccn.org/evidenceblocks/. [Accessed August 3, 2016].
6. [6] Swanick M, Strang D. Third party drug assessors: influential new voices in the value debate. Available from: http://www.pwc.com/us/en/health-industries/health-research-institute/publications/third-party-drug-assessors.html. [Accessed August 3, 2016].
7. [7] Westrich K. Current landscape: value assessment frameworks. Available from: http://www.npcnow.org/system/files/research/download/npc-current-landscape-value-assessment-frameworks-final.pdf/. [Accessed July 15, 2016].
8. [8] Angelis, A., Kanavos, P., Critique of the American Society of Clinical Oncology value assessment framework for cancer treatments: putting methodologic robustness first. J Clin Oncol 34 (2016), 2935–2936.
9. [9] Basch, E., Toward a patient-centered value framework in oncology. JAMA 315 (2016), 2073–2074.
10. [10] Neumann, P.J., Cohen, J.T., Measuring the value of prescription drugs. N Engl J Med 373 (2015), 2595–2597.
11. [11] Schnipper, L.E., Bastian, A., New frameworks to assess value of cancer care: strengths and limitations. Oncologist 21 (2016), 654–658.
12. [12] Perrone M. Breakthrough cholesterol drugs fizzle amid price pushback. Available from: http://bigstory.ap.org/article/a15448a756dc4bfc9bc78174b14ccb6f/breakthrough-cholesterol-drugs-fizzle-amid-price-pushback. [Accessed August 13, 2016].
13. [13] Caffrey MK. For now, PBMs just say no to high-cost PCSK9 inhibitors. Available from: http://www.ajmc.com/journals/evidence-based-diabetes-management/2015/september-2015/for-now-pbms—just-say-no-to—high-cost-pcsk9—inhibitors. [Accessed August 13, 2016].
14. [14] National Health Council. The patient voice in value: the National Health Council patient-centered value model rubric. Available from: http://www.nationalhealthcouncil.org/sites/default/files/Value-Rubric.pdf. [Accessed July 10, 2016].
15. [15] Longacre ML, Charap ES, Buzaglo JS, et al. Defining value in oncology: perspectives from patients with metastatic breast cancer. Available from: http://www.cancersupportcommunity.org/sites/default/files/uploads/our-research/presentations/access-to-care/avbcc_value_poster_.pdf/. [Accessed July 15, 2016].
16. [16] Schnipper, L.E., Davidson, N.E., Wollins, D.S., et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34 (2016), 2925–2934.
17. [17] National Comprehensive Cancer Network. NCCN guidelines for patients. Multiple myeloma, version 1.2016. Available from: https://www.nccn.org/patients/guidelines/myeloma/files/assets/basic-html/page-1.html#. [Accessed August 10, 2016].
18. [18] Institute for Clinical and Economic Review. Multiple myeloma: final evidence report and meeting summary. Available from: https://icer-review.org/material/mm-final-report/. [Accessed August 10, 2016].
19. [19] Seidman J, Choe SH. Most health plans do not use existing value frameworks to make coverage decisions. Available from: http://avalere.com/expertise/life-sciences/insights/most-health-plans-do-not-use-value-frameworks-to-make-coverage-decisions/. [Accessed August 3, 2016].
20. [20] Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
21. [21] Ades, A., Caldwell, D.M., Reken, S., et al. Evidence synthesis for decision making: a reviewer's checklist. Med Decis Making 33 (2013), 679–691.
22. [22] McKenna, C., Soares, M., Claxton, K., et al. Unifying research and reimbursement decisions: case studies demonstrating the sequence of assessment and judgments required. Value Health 18 (2015), 865–875.
23. [23] International Society for Pharmacoeconomics and Outcomes Research. Initiative on US value assessment frameworks. Available from: http://www.ispor.org/ValueAssessmentFrameworks/Index. [Accessed August 20, 2016].